A team of our lawyers who counsel on Over-the-Counter (OTC) drug regulation will discuss the long-awaited OTC drug monograph reform that was part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which U.S. President Trump signed into law on 27 March 2020.
This on-demand presentation will review the OTC monograph reform legislation and the following key areas:
- Innovation and marketing opportunities
- New user fees
- Streamlined review for OTC drugs
- Market impact
- How to prepare
OTC drug companies will want to review this monograph reform legislation closely, and begin preparing immediately for the innovation opportunities, as well as the regulatory and competitive risks, created by the new law. Listen now